Boehringer starts patient enrolment in dabigatran Phase III trial to prevent ESUS

Boehringer Ingelheim has started patient enrolment in the RE-SPECT ESUS Phase III trial designed to evaluate the efficacy and safety of dabigatran etexilate to prevent recurrent embolic stroke of undetermined source (ESUS).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news